Jubilant Pharmova Limited announced its financial results for the quarter and full year ended March 31, 2026, reporting strong revenue growth across key business segments driven by expansion in sterile injectables, allergy immunotherapy and generics. The company’s Board of Directors has also recommended a dividend of Rs 5 per equity share for FY26. For the financial year ended March 31, 2026, Jubilant Pharmova reported consolidated revenue of Rs 8,280 crore, reflecting a year-on-year growth of 14 percent. EBITDA for the year increased by 8 percent to Rs. 1,326 crore, while normalized profit after tax rose 7 percent to Rs 442 crore.
Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia said the company witnessed strong momentum across several businesses during the year, particularly in CDMO sterile injectables, allergy immunotherapy and generics. They highlighted that growth in sterile injectables was supported by increased revenue generation from the new production lines at the Spokane facility in the United States.
The company also reported rapid expansion in its Ruby-Fill® installations within the radiopharmaceuticals segment, while demand for allergy immunotherapy products strengthened across both U.S. and international markets. Jubilant Pharmova additionally announced progress in its strategic partnership with Pierre Fabre aimed at expanding biologics and antibody-drug conjugate capabilities in Europe.
During FY26, the company integrated its drug discovery and API businesses under Jubilant Biosys Limited to improve operational efficiencies and strengthen its CRDMO positioning among global pharmaceutical and biotechnology clients. In the fourth quarter of FY26, revenue rose 19 percent year-on-year to Rs 2,290 crore, supported by growth in radiopharmaceuticals, allergy immunotherapy, sterile injectables and generics. EBITDA for the quarter stood at Rs 363 crore, while normalized PAT reached Rs 129 crore.
The radiopharmaceuticals business continued to maintain a strong position in the SPECT imaging market despite temporary supply disruptions at the Montreal facility. The company confirmed that commercial batch production at Montreal is expected to resume during the current quarter following successful media fills and remediation measures.
In the CDMO sterile injectables business, the Spokane facility delivered one of the fastest revenue ramp-ups in the industry, with revenues rising 48 percent during FY26. Jubilant Pharmova also confirmed onboarding of one of the world’s largest oncology products on its Line 3 facility, with commercial production expected to begin in late FY27 subject to regulatory approvals. The generics business also posted significant gains, with EBITDA growing 250 percent during the year as profitability improved substantially.
Jubilant Pharmova Limited is a multinational pharmaceutical company specializing in radiopharmaceuticals, allergy immunotherapy, sterile injectable CDMO, and CRDMO services. It operates multiple manufacturing facilities serving regulated markets worldwide, employing approximately 5,500 professionals across its global operations.
